Search

Displaying results 6161 - 6170 of 7895 in total
  1. Drug

    LYT-200

    go.drugbank.com/drugs/DB18179
    Investigational

    LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

  2. Drug

    ATI-1013

    go.drugbank.com/drugs/DB18185
    Investigational

    ATI-1013 is a fully human nicotine-specific monoclonal antibody.

  3. Drug

    CLBS12

    go.drugbank.com/drugs/DB18192
    Investigational

    CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.

  4. Drug

    GX-G8

    go.drugbank.com/drugs/DB18196
    Experimental

    GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.

  5. Drug

    ST-003

    go.drugbank.com/drugs/DB18197
    Experimental

    ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.

  6. Drug

    FCX-013

    go.drugbank.com/drugs/DB18218
    Investigational

    FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).

  7. Drug

    CKD-504

    go.drugbank.com/drugs/DB18235
    Investigational

    CKD-504 is a novel, selective histone deacetylase 6 inhibitor.

  8. Drug

    DR-01

    go.drugbank.com/drugs/DB18258
    Investigational

    DR-01 is a monoclonal antibody directed against human CD94.

  9. Drug

    MRT5005

    go.drugbank.com/drugs/DB18260
    Investigational

    MRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI).

  10. Drug

    MPB-1523

    go.drugbank.com/drugs/DB18334
    Investigational

    MPB-1523 is a contrast agent comprising PEGylated iron oxide nanoparticles.[L48161]